Table 1.
Demographics, classification and treatment variables
| Characteristics | Complete dataset (n = 142) |
PAH (n = 90) |
PAH with comorbidities (n = 52) |
p-value |
|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||
| Female sex no. [%] | 87 (61.3) | 66 (73.3%) | 21 (40.4%) | < 0.0001 |
| Diagnostic group of PAH [%] | ||||
| IPAH | 44 (31%) | 44 (48.8%) | ||
| HPAH | 4 (2.8%) | 4 (4.4%) | ||
| DPAH | 1 (0.7%) | 1 (1.1%) | ||
| APAH | 41 (28.9%) | 41 (45.6%) | ||
| PAH with cardiac comorbidities | 33 (23.3%) | 33 (63.5%) | ||
| PAH with pulmonary comorbidities | 19 (13.4%) | 19 (36.5%) | ||
| Group of APAH [%] | ||||
| Connective tissue diseases | 37 (26.1%) | 37 (41.1%) | ||
| HIV | 1 (2.5%) | 1 (1.1%) | ||
| Portal hypertension | 3 (0.7%) | 3 (3.3%) | ||
| No. of PAH drugs | 0.82 | |||
| Monotherapy | 90 (63.4%) | 56 (62.2%) | 34 (65.4%) | |
| Double combination | 50 (35.2%) | 33 (36.7%) | 17 (32.7%) | |
| Triple combination | 2 (1.4%) | 1 (1.1%) | 1 (1.9%) | |
| Type of PAH drug at diagnosis [%] | 0.02 | |||
| Calcium channel blocker | 12 (8.5%) | 4 (4.4%) | 8 (15.4%) | |
| Endothelin receptor antagonist | 62 (43.7%) | 48 (53.3%) | 14 (26.9%) | |
| Phosphodiesterase 5 inhibitor | 108 (76.1%) | 65 (72.2%) | 43 (82.7%) | |
| Prostacyclin | 2 (1.4%) | 1 (1.1%) | 1 (1.9%) | |
| Soluble guanylate cyclase stimulator | 7 (4.9%) | 3 (3.3%) | 4 (7.7%) | |
| Oxygen treatment | 53 (37.3%) | 25 (27.8%) | 28 (53.8%) | |
| Anticoagulants | 116 (81.7%) | 69 (76.7%) | 47 (90.4%) | 0.042 |
| Diuretics | 108 (76.1%) | 63 (70.0%) | 45 (86.5%) | 0.026 |
In case of missing data, sample sizes are given in the column of n. sample size is given in case of missing values. IPAH idiopathic pulmonary arterial hypertension, HPAH heritable pulmonary arterial hypertension, DPAH drug-induced pulmonary arterial hypertension, APAH associated pulmonary arterial hypertension, PAH pulmonary arterial hypertension